tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

Vertex Pharmaceuticals announces EC approval for Alyftrek for CF treatment
The FlyVertex Pharmaceuticals announces EC approval for Alyftrek for CF treatment
2d ago
VRTX
Cautious Hold Rating for Vertex Pharmaceuticals Amid Limited Uptake and Insurance Challenges for Journavx
PremiumRatings
Cautious Hold Rating for Vertex Pharmaceuticals Amid Limited Uptake and Insurance Challenges for Journavx
8d ago
VRTX
Cautious Hold Rating on Vertex Pharmaceuticals Amid Promising Diabetes Treatment and Market Uncertainties
PremiumRatings
Cautious Hold Rating on Vertex Pharmaceuticals Amid Promising Diabetes Treatment and Market Uncertainties
9d ago
VRTX
Hold Rating on Vertex Pharmaceuticals: Balancing Promising Efficacy with Scalability and Commercial Viability Concerns for Zimislecel Therapy
PremiumRatings
Hold Rating on Vertex Pharmaceuticals: Balancing Promising Efficacy with Scalability and Commercial Viability Concerns for Zimislecel Therapy
9d ago
VRTX
Vertex Pharmaceuticals’ Zimislecel Shows Promising Advances in Type 1 Diabetes Treatment, Earning a Buy Rating
PremiumRatings
Vertex Pharmaceuticals’ Zimislecel Shows Promising Advances in Type 1 Diabetes Treatment, Earning a Buy Rating
10d ago
VRTX
Vertex, Ono announce license agreement for povetacicept in Japan and South Korea
PremiumThe FlyVertex, Ono announce license agreement for povetacicept in Japan and South Korea
10d ago
VRTX
Vertex Pharmaceuticals price target lowered to $420 from $423 at RBC Capital
Premium
The Fly
Vertex Pharmaceuticals price target lowered to $420 from $423 at RBC Capital
16d ago
VRTX
Vertex Pharmaceuticals: Promising Growth with Strong Demand and Strategic Pipeline Developments
Premium
Ratings
Vertex Pharmaceuticals: Promising Growth with Strong Demand and Strategic Pipeline Developments
17d ago
VRTX
Vertex Pharmaceuticals: Promising Product Launches and Pipeline Developments Justify Buy Rating
PremiumRatings
Vertex Pharmaceuticals: Promising Product Launches and Pipeline Developments Justify Buy Rating
22d ago
VRTX
Vertex Pharmaceuticals: Promising Outlook with Strong Pipeline and Strategic Launch Initiatives
PremiumRatings
Vertex Pharmaceuticals: Promising Outlook with Strong Pipeline and Strategic Launch Initiatives
24d ago
VRTX
Vertex Pharmaceuticals’ Povetacicept: A Promising Contender in IgA Nephropathy Treatment with Strong Market Potential
PremiumRatings
Vertex Pharmaceuticals’ Povetacicept: A Promising Contender in IgA Nephropathy Treatment with Strong Market Potential
24d ago
VRTX
Vertex Pharmaceuticals: Strong Performance and Promising Pipeline Drive Buy Rating
PremiumRatings
Vertex Pharmaceuticals: Strong Performance and Promising Pipeline Drive Buy Rating
27d ago
VRTX
Vertex Pharmaceuticals presents new data on ALYFTREK at ECFS Conference
PremiumThe FlyVertex Pharmaceuticals presents new data on ALYFTREK at ECFS Conference
27d ago
VRTX
Vertex Pharmaceuticals: Strong Buy Rating Backed by Leadership in NAV1.8 Inhibitors and Strategic Collaborations
Premium
Ratings
Vertex Pharmaceuticals: Strong Buy Rating Backed by Leadership in NAV1.8 Inhibitors and Strategic Collaborations
1M ago
VRTX
BMO says Eli Lilly ‘well-priced deal’ to expand presence in pain a positive
Premium
The Fly
BMO says Eli Lilly ‘well-priced deal’ to expand presence in pain a positive
1M ago
LLY
VRTX
Vertex Pharmaceuticals downgraded to Hold from Buy at Erste Group
PremiumThe Fly
Vertex Pharmaceuticals downgraded to Hold from Buy at Erste Group
1M ago
VRTX
Vertex Pharmaceuticals Launches $4 Billion Stock Buyback
PremiumCompany Announcements
Vertex Pharmaceuticals Launches $4 Billion Stock Buyback
1M ago
8K
VRTX
Vertex Pharmaceuticals: Strategic Positioning and Promising Growth Prospects Underpin Buy Rating
PremiumRatings
Vertex Pharmaceuticals: Strategic Positioning and Promising Growth Prospects Underpin Buy Rating
2M ago
VRTX
Vertex Pharmaceuticals Holds Annual Shareholder Meeting
PremiumCompany Announcements
Vertex Pharmaceuticals Holds Annual Shareholder Meeting
2M ago
8K
VRTX
Vertex Pharmaceuticals: Strong Growth and Promising Pipeline Justify Buy Rating
PremiumRatingsVertex Pharmaceuticals: Strong Growth and Promising Pipeline Justify Buy Rating
2M ago
VRTX
Biotech Alert: Searches spiking for these stocks today
Premium
The Fly
Biotech Alert: Searches spiking for these stocks today
2M ago
BOLT
HRTX
Biotech Alert: Searches spiking for these stocks today
Premium
The Fly
Biotech Alert: Searches spiking for these stocks today
2M ago
MRK
ATHE

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >